Allist Pharmaceuticals, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Shanghai China (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2016
NCT02973763
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Allist Pharmaceuticals, Inc. | Shanghai Allist Pharmaceutical Technology Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 7